RE: RE: Drop20 Aug 2019 14:27
Not invested here but when I started investing (only in October 2018) this was one of the shares that caught my eye, like a few others, and I've followed it ever since in order to prove my ability to pick good shares (so far with this one I would be break even). I think the drop can be partially explained because there are still inconsistencies in the efficacy of the drug which is clearly impacted by the dosing and more work on the dosing is required. The inconsistencies are not helped by, and may even be caused by, the test / protocol (clinical trial protocol), as per the following from the RNS:
"The evaluation of the response after two injections was compromised by the design of the experiment, where blood samples were taken too soon after the second injection. However, the results did indicate a trend towards the appearance of OVA antibodies in these tests as well."
I really hope this does well as it will validate my methodology for picking shares.